Methylation of the candidate biomarker TCF21 is very frequent across a spectrum of early-stage nonsmall cell lung cancers

Kristy L. Richards, Baili Zhang, Menghong Sun, Wenli Dong, Jennifer Churchill, Linda L. Bachinski, Charmaine D. Wilson, Keith A. Baggerly, Guosheng Yin, D. Neil Hayes, Ignacio I. Wistuba, Ralf Krahe

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Background: The transcription factor TCF21 is involved in mesenchymal-to-epithelial differentiation and was shown to be aberrantly hypermethylated in lung and head and neck cancers. Because of its reported high frequency of hypermethylation in lung cancer, further characterization of the stages and types of nonsmall cell lung cancer (NSCLC) that are hypermethylated and the frequency of hypermethylation and associated "second hits" were assessed. Methods: TCF21 promoter hypermethylation in 105 NSCLC including various stages and histologies in smokers and nonsmokers was determined. In addition, TCF21 loss of heterozygosity and mutational status were examined. Twenty-two cancer cell lines from varied tissue origins were also assayed. The NSCLC results were validated and expanded by examining TCF21 immunohistochemical expression on a tissue microarray containing 300 NSCLC cases. Results: Overall, 81% of NSCLC samples showed TCF21 promoter hypermethylation, and 84% showed decreased TCF21 protein expression. Multivariate analysis showed that TCF21 expression, although below normal in both histologies, was lower in adenocarcinoma than in squamous cell carcinoma and was not independently correlated with sex, smoking, and EGFR mutation status or with clinical outcome. Cell lines from other cancer types also showed frequent TCF21 promoter hypermethylation. Conclusions: Hypermethylation and decreased expression of TCF21 were tumor specific and very frequent in all NSCLCs, even early-stage disease, thus making TCF21 a potential candidate methylation biomarker for early-stage NSCLC screening. TCF21 hypermethylation in a variety of tumor cell lines suggests it may also be a valuable methylation biomarker in other tumor types.

Original languageEnglish
Pages (from-to)606-617
Number of pages12
JournalCancer
Volume117
Issue number3
DOIs
StatePublished - 1 Feb 2011

Fingerprint

Non-Small Cell Lung Carcinoma
Methylation
Biomarkers
Lung Neoplasms
Neoplasms
Histology
Cell Line
Loss of Heterozygosity
Head and Neck Neoplasms
Tumor Cell Line
Early Detection of Cancer
Squamous Cell Carcinoma
Adenocarcinoma
Transcription Factors
Multivariate Analysis
Smoking
Mutation
Proteins

Keywords

  • TCF21
  • biomarker
  • lung cancer
  • methylation
  • screening

Cite this

Richards, Kristy L. ; Zhang, Baili ; Sun, Menghong ; Dong, Wenli ; Churchill, Jennifer ; Bachinski, Linda L. ; Wilson, Charmaine D. ; Baggerly, Keith A. ; Yin, Guosheng ; Hayes, D. Neil ; Wistuba, Ignacio I. ; Krahe, Ralf. / Methylation of the candidate biomarker TCF21 is very frequent across a spectrum of early-stage nonsmall cell lung cancers. In: Cancer. 2011 ; Vol. 117, No. 3. pp. 606-617.
@article{a6b4f18145d24e90a401141b275afd66,
title = "Methylation of the candidate biomarker TCF21 is very frequent across a spectrum of early-stage nonsmall cell lung cancers",
abstract = "Background: The transcription factor TCF21 is involved in mesenchymal-to-epithelial differentiation and was shown to be aberrantly hypermethylated in lung and head and neck cancers. Because of its reported high frequency of hypermethylation in lung cancer, further characterization of the stages and types of nonsmall cell lung cancer (NSCLC) that are hypermethylated and the frequency of hypermethylation and associated {"}second hits{"} were assessed. Methods: TCF21 promoter hypermethylation in 105 NSCLC including various stages and histologies in smokers and nonsmokers was determined. In addition, TCF21 loss of heterozygosity and mutational status were examined. Twenty-two cancer cell lines from varied tissue origins were also assayed. The NSCLC results were validated and expanded by examining TCF21 immunohistochemical expression on a tissue microarray containing 300 NSCLC cases. Results: Overall, 81{\%} of NSCLC samples showed TCF21 promoter hypermethylation, and 84{\%} showed decreased TCF21 protein expression. Multivariate analysis showed that TCF21 expression, although below normal in both histologies, was lower in adenocarcinoma than in squamous cell carcinoma and was not independently correlated with sex, smoking, and EGFR mutation status or with clinical outcome. Cell lines from other cancer types also showed frequent TCF21 promoter hypermethylation. Conclusions: Hypermethylation and decreased expression of TCF21 were tumor specific and very frequent in all NSCLCs, even early-stage disease, thus making TCF21 a potential candidate methylation biomarker for early-stage NSCLC screening. TCF21 hypermethylation in a variety of tumor cell lines suggests it may also be a valuable methylation biomarker in other tumor types.",
keywords = "TCF21, biomarker, lung cancer, methylation, screening",
author = "Richards, {Kristy L.} and Baili Zhang and Menghong Sun and Wenli Dong and Jennifer Churchill and Bachinski, {Linda L.} and Wilson, {Charmaine D.} and Baggerly, {Keith A.} and Guosheng Yin and Hayes, {D. Neil} and Wistuba, {Ignacio I.} and Ralf Krahe",
year = "2011",
month = "2",
day = "1",
doi = "10.1002/cncr.25472",
language = "English",
volume = "117",
pages = "606--617",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

Richards, KL, Zhang, B, Sun, M, Dong, W, Churchill, J, Bachinski, LL, Wilson, CD, Baggerly, KA, Yin, G, Hayes, DN, Wistuba, II & Krahe, R 2011, 'Methylation of the candidate biomarker TCF21 is very frequent across a spectrum of early-stage nonsmall cell lung cancers', Cancer, vol. 117, no. 3, pp. 606-617. https://doi.org/10.1002/cncr.25472

Methylation of the candidate biomarker TCF21 is very frequent across a spectrum of early-stage nonsmall cell lung cancers. / Richards, Kristy L.; Zhang, Baili; Sun, Menghong; Dong, Wenli; Churchill, Jennifer; Bachinski, Linda L.; Wilson, Charmaine D.; Baggerly, Keith A.; Yin, Guosheng; Hayes, D. Neil; Wistuba, Ignacio I.; Krahe, Ralf.

In: Cancer, Vol. 117, No. 3, 01.02.2011, p. 606-617.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Methylation of the candidate biomarker TCF21 is very frequent across a spectrum of early-stage nonsmall cell lung cancers

AU - Richards, Kristy L.

AU - Zhang, Baili

AU - Sun, Menghong

AU - Dong, Wenli

AU - Churchill, Jennifer

AU - Bachinski, Linda L.

AU - Wilson, Charmaine D.

AU - Baggerly, Keith A.

AU - Yin, Guosheng

AU - Hayes, D. Neil

AU - Wistuba, Ignacio I.

AU - Krahe, Ralf

PY - 2011/2/1

Y1 - 2011/2/1

N2 - Background: The transcription factor TCF21 is involved in mesenchymal-to-epithelial differentiation and was shown to be aberrantly hypermethylated in lung and head and neck cancers. Because of its reported high frequency of hypermethylation in lung cancer, further characterization of the stages and types of nonsmall cell lung cancer (NSCLC) that are hypermethylated and the frequency of hypermethylation and associated "second hits" were assessed. Methods: TCF21 promoter hypermethylation in 105 NSCLC including various stages and histologies in smokers and nonsmokers was determined. In addition, TCF21 loss of heterozygosity and mutational status were examined. Twenty-two cancer cell lines from varied tissue origins were also assayed. The NSCLC results were validated and expanded by examining TCF21 immunohistochemical expression on a tissue microarray containing 300 NSCLC cases. Results: Overall, 81% of NSCLC samples showed TCF21 promoter hypermethylation, and 84% showed decreased TCF21 protein expression. Multivariate analysis showed that TCF21 expression, although below normal in both histologies, was lower in adenocarcinoma than in squamous cell carcinoma and was not independently correlated with sex, smoking, and EGFR mutation status or with clinical outcome. Cell lines from other cancer types also showed frequent TCF21 promoter hypermethylation. Conclusions: Hypermethylation and decreased expression of TCF21 were tumor specific and very frequent in all NSCLCs, even early-stage disease, thus making TCF21 a potential candidate methylation biomarker for early-stage NSCLC screening. TCF21 hypermethylation in a variety of tumor cell lines suggests it may also be a valuable methylation biomarker in other tumor types.

AB - Background: The transcription factor TCF21 is involved in mesenchymal-to-epithelial differentiation and was shown to be aberrantly hypermethylated in lung and head and neck cancers. Because of its reported high frequency of hypermethylation in lung cancer, further characterization of the stages and types of nonsmall cell lung cancer (NSCLC) that are hypermethylated and the frequency of hypermethylation and associated "second hits" were assessed. Methods: TCF21 promoter hypermethylation in 105 NSCLC including various stages and histologies in smokers and nonsmokers was determined. In addition, TCF21 loss of heterozygosity and mutational status were examined. Twenty-two cancer cell lines from varied tissue origins were also assayed. The NSCLC results were validated and expanded by examining TCF21 immunohistochemical expression on a tissue microarray containing 300 NSCLC cases. Results: Overall, 81% of NSCLC samples showed TCF21 promoter hypermethylation, and 84% showed decreased TCF21 protein expression. Multivariate analysis showed that TCF21 expression, although below normal in both histologies, was lower in adenocarcinoma than in squamous cell carcinoma and was not independently correlated with sex, smoking, and EGFR mutation status or with clinical outcome. Cell lines from other cancer types also showed frequent TCF21 promoter hypermethylation. Conclusions: Hypermethylation and decreased expression of TCF21 were tumor specific and very frequent in all NSCLCs, even early-stage disease, thus making TCF21 a potential candidate methylation biomarker for early-stage NSCLC screening. TCF21 hypermethylation in a variety of tumor cell lines suggests it may also be a valuable methylation biomarker in other tumor types.

KW - TCF21

KW - biomarker

KW - lung cancer

KW - methylation

KW - screening

UR - http://www.scopus.com/inward/record.url?scp=79251487851&partnerID=8YFLogxK

U2 - 10.1002/cncr.25472

DO - 10.1002/cncr.25472

M3 - Article

C2 - 20945327

AN - SCOPUS:79251487851

VL - 117

SP - 606

EP - 617

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3

ER -